An adjuvant is essentially a substance that stimulates the immune response to an antigen without having any antigenic effects itself. The phrase “adjuvant” origins from the Latin word “adjuvare”, which means “help” or “helper”.
Learn more about adjuvants and about Isconova’s contribution in the area
The new generation of ISCOM technology has opened up new applications in immunological research by overcoming drawbacks once associated with problematic formulations. Isconova’s next-gen adjuvant is easily handled with any antigen.
Isconova’s technology plattform is available for licensing for many veterinary vaccine development segments. Our tailored business collaboration models are designed to fit your specific requirements and circumstances.
With its improved performance safety windows, Isconova’s state-of-the-art adjuvant technology platform opens up new possibilities for human vaccine development.
Isconova has been awarded the 2010 Bona Postulata Prize, for being a growing company with a great potential to become even more successful. The Bona Postulata Prize [1] is not intended to be a reward [...]
Read moreUppsala, Sweden, November 23 2009 – At a time like this, when the global society is under a pandemic influenza threat, the need for a safe, effective and antigen dose-sparing adjuvant becomes critical. Isconova announced [...]
Read more
The AbISCO® adjuvant consistently induces the highest proliferation index and high production levels of antibodies.